Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus - PubMed (original) (raw)
Review
Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus
Muhammad A Abdul-Ghani et al. Endocr Pract. 2008 Sep.
Abstract
Objective: To review the renal handling of glucose and the role of inhibition of a sodium-glucose transporter (SGLT2) in the treatment of type 2 diabetes mellitus (T2DM).
Methods: We review the published data about (1) the filtration and reabsorption of glucose by the kidneys in normal subjects and patients with diabetes; (2) the deleterious effects of long-term elevation of plasma glucose levels on muscle and hepatic insulin sensitivity and beta cell function (that is, glucotoxicity); (3) the effect of inhibiting the SGLT2 transporter on the induction of glycosuria, glycemic control, insulin resistance, and beta cell dysfunction in animals and humans with diabetes; and (4) the safety of SGLT2 inhibition as a therapeutic modality to treat human T2DM.
Results: Studies in animal models of diabetes document the efficacy of the SGLT2 inhibitors in inducing glycosuria, decreasing both fasting and postprandial glucose levels, augmenting beta cell function, and enhancing hepatic and muscle insulin sensitivity. In human T2DM, short-term studies with dapagliflozin (12 weeks) and sergliflozin (2 weeks) have confirmed the efficacy of these agents in improving glycemic control. Excessive urinary electrolyte or water loss, plasma electrolyte disturbances, and hypoglycemia were not observed.
Conclusion: SGLT2 inhibitors represent a promising approach to the treatment of T2DM. They have the potential to be used as monotherapy, as well as in combination with all approved antidiabetic agents. Because their mechanism of action is independent of the severity of beta cell dysfunction or insulin resistance, efficacy should not decline with progressive beta cell failure or in the presence of severe insulin resistance.
Similar articles
- Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E, Ogasawara H. Kurosaki E, et al. Pharmacol Ther. 2013 Jul;139(1):51-9. doi: 10.1016/j.pharmthera.2013.04.003. Epub 2013 Apr 4. Pharmacol Ther. 2013. PMID: 23563279 Review. - Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.
Katsuno K, Fujimori Y, Takemura Y, Hiratochi M, Itoh F, Komatsu Y, Fujikura H, Isaji M. Katsuno K, et al. J Pharmacol Exp Ther. 2007 Jan;320(1):323-30. doi: 10.1124/jpet.106.110296. Epub 2006 Oct 18. J Pharmacol Exp Ther. 2007. PMID: 17050778 - Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.
Chen LH, Leung PS. Chen LH, et al. Diabetes Obes Metab. 2013 May;15(5):392-402. doi: 10.1111/dom.12064. Epub 2013 Feb 6. Diabetes Obes Metab. 2013. PMID: 23331516 Review. - SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
Jabbour SA. Jabbour SA. Postgrad Med. 2014 Jan;126(1):111-7. doi: 10.3810/pgm.2014.01.2731. Postgrad Med. 2014. PMID: 24393758 Review. - SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.
Ghosh RK, Ghosh SM, Chawla S, Jasdanwala SA. Ghosh RK, et al. J Clin Pharmacol. 2012 Apr;52(4):457-63. doi: 10.1177/0091270011400604. Epub 2011 May 4. J Clin Pharmacol. 2012. PMID: 21543663 Review.
Cited by
- Safety of Empagliflozin: An Individual Participant-Level Data Meta-Analysis from Four Large Trials.
Wanner C, Iliev H, Duarte N, Schueler E, Soares AR, Thanam V, Pfarr E. Wanner C, et al. Adv Ther. 2024 Jul;41(7):2826-2844. doi: 10.1007/s12325-024-02879-w. Epub 2024 May 21. Adv Ther. 2024. PMID: 38771475 Free PMC article. - SGLT2 inhibitors, intrarenal hypoxia and the diabetic kidney: insights into pathophysiological concepts and current evidence.
Papaetis GS. Papaetis GS. Arch Med Sci Atheroscler Dis. 2023 Dec 30;8:e155-e168. doi: 10.5114/amsad/176658. eCollection 2023. Arch Med Sci Atheroscler Dis. 2023. PMID: 38283924 Free PMC article. - Natural products targeting inflammation-related metabolic disorders: A comprehensive review.
Nainu F, Frediansyah A, Mamada SS, Permana AD, Salampe M, Chandran D, Emran TB, Simal-Gandara J. Nainu F, et al. Heliyon. 2023 Jun 2;9(6):e16919. doi: 10.1016/j.heliyon.2023.e16919. eCollection 2023 Jun. Heliyon. 2023. PMID: 37346355 Free PMC article. Review. - GLP-1 receptor agonists, SGLT-2 inhibitors, and obstructive sleep apnoea: can new allies face an old enemy?
Papaetis GS. Papaetis GS. Arch Med Sci Atheroscler Dis. 2023 Feb 28;8:e19-e34. doi: 10.5114/amsad/161170. eCollection 2023. Arch Med Sci Atheroscler Dis. 2023. PMID: 37153372 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical